

Myeloproliferative Neoplasien (MPN)

GSG-MPN-Register und Biomaterialbank

ET

MF

High risk ET

CALR-
mutiert

Accelerated phase MPN
(10-19% Blasten PB od. KM)

[MK-3543-007](#)

A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) versus Hydroxyurea in Previously-Untreated Essential Thrombocythemia

[MK-3543-006](#)

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea

[INCA 33989-101](#)

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

[JNJ-88549968](#)

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

[FAMY \(IIT\)](#)

Eine multizentrische, offene Phase 1/2 Studie zur Beurteilung der Wirksamkeit und Sicherheit von Fedratinib in Kombination mit CC-486 bei Patienten mit Myelofibrose in akzellerierter Phase